Sample
Sample
1. PURPOSE
1.1 To define the procedure for performing, documenting, approving, and archiving a medical device risk
analysis.
2. SCOPE
2.1 All medical devices manufactured and/or distributed by Company that are used in clinical trials or
placed on the market or put into service.
3. RESPONSIBILITY
3.1 Technical authorities (individuals at Company with technical expertise) and persons identified in the
risk management plan are responsible for participating in the Risk Analysis and reviewing the Risk
Analysis Report.
3.2 R&D Project Leaders are responsible for organizing a Risk Analysis at least at the start of the
development process and at the end. They shall also revise the Risk Analysis whenever important
information becomes available.
3.3 R&D Project Leaders are responsible for including the Project Risk Analyses in the Project
documentation.
3.4 Document Control is responsible for including the Product Risk Analysis Report into the Technical
Documentation.
3.5 Document Control will assure that the Product Risk Analysis Report is reviewed on an biannual basis.
5.1 None.
6.1 None.
7. DOCUMENTATION REQUIREMENTS
8. DEFINITIONS
8.3 RISK is the probable rate of occurrence of a hazard causing harm and the degree of severity of the
harm. RISK = PROBABILITY OF THE HAZARD AND SEVERITY OF THE HARM.
8.6 RISK ASSESSMENT is the EVALUATION of all the risks identified, and is the process by which the
manufacturer decides whether the device is to be considered as safe.
8.7 RISK MANAGEMENT the process by which the manufacturer reduces and CONTROLS the risk on
an ongoing basis.
9. PROCESS - GENERAL
9.1 A Risk Management Plan is written at the end of the Feasibility Stage or at the beginning of the
Development Phase of product development as defined by 12-0050-SOP-1.0. The plan defines the
documentation required for the risk analysis report and the group responsible for reviewing and
approving the risk analysis.
9.2 A Risk Analysis is performed during the Development Stage after the product requirements
definition/specification has been completed. Additional Risk Analyses are performed during the
development process as defined in the Risk Management Plan or when there are significant changes in
the product specifications.
10.1.1 The project manager should determine who is responsible for writing the risk managment
plan.
10.1.2 The following items are defined and documented in the Risk Management Plan:
10.1.2.2 the general strategy taken to minimize risk(This may include design changes,
clinical trials, input from experts, etc.)
• Project Leader
• R&D Technical Authority
• Engineering Technical Authority
• Manufacturing Technical Authority
• QA/QC Technical Authority
• Clinical Affairs Technical Authority
• Marketing Technical Authority
• Regulatory USA
• Regulatory Europe
• Other individuals as identified by the participants.
10.1.2.4 the documentation (test reports, standards, etc.) to be reviewed before performing
the risk analysis.
10.1.2.8 hazard/measurements list(s) selected. These are lists defined in standards or created
for other products used.
10.1.3.1 Risk Management Plans are formatted as ENGR documents from Engineering or
Research and Development
10.1.3.2 The only approvals required are the project leader, the technical authority in
Research and Development, and an appropriate member of the clinical research
group.
10.2.1 Identification of hazards based on the functions and characteristics of the product.
10.2.1.2 Possible hazards are identified for each function and characteristic:
10.2.1.2.1 Possible hazards are identified for normal conditions and (single) fault
conditions.
10.2.1.2.2 The list shall include hazards such as misuse, stability problems, batch
to batch variations, power failure.
10.2.2.1 Each hazard results in a specific physical injury and or damage to health or property